We restore endothelial cell function.
Welcome
Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium.
Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.
Latest News
Pantherna Therapeutics to present at BIO-Europe 2019
Dr. Klaus Giese (CEO) will present in the Start-Up Slam at the BIO-Europe 2019 conference in Hamburg on Tuesday, Nov 12.
Team
Contact
Get in touch
Pantherna Therapeutics GmbH
Neuendorfstrasse 20b
D-16761 Hennigsdorf
Germany
Telephone: +49(0)3302-202 240-0
Telefax: +49(0)3302-202 240-1
E-Mail: contact@pantherna-therapeutics.com
Managing Directors: Dr. Klaus Giese, Dr. Jörg Kaufmann, Dr. Gerrit Maass
How can we help?
Public Funding
Pantherna is supported by public funding from the EU (EFRE). EFRE is provided by the State Brandenburg through the following programs “ProFIT and Gründung Innovativ:
#80174940 „Förderung von Forschung, Innovationen und Technologien ProFIT (ab 2014) ProFIT: Zelltyp-spezifische Expression therapeutischer Proteine (AP 1, 2, 3, 4)“
#80174941 „Förderung von Forschung, Innovationen und Technologien ProFIT (ab 2014) ProFIT: Zelltyp-spezifische Expression therapeutischer Proteine (AP 5 und 6)“
#85026035 „Gründung Innovativ 2015 – 2020 Optimierung der Herstellung von mRNA-Konstrukten für die in-vivo Expression von therapeutischen Proteinen i. d. Vaskulation“
